AstraZeneca's Coronavirus Vaccine Candidate Steps Forward Again
A leader in the race to develop a vaccine that could bring the ongoing COVID-19 pandemic to a close has taken another important step forward. AstraZeneca (NYSE: AZN) has begun a late-stage clinical trial in the U.S. with its coronavirus vaccine candidate, AZD1222, the company announced Monday.
Developed in partnership with Oxford University, AZD1222 employs the husk of an inactivated virus to deliver genetic material. Injections with the viral vector-based vaccine candidate appear to train human immune systems to recognize SARS-CoV-2 and shut it down before it leads to COVID-19.
Image source: Getty Images.
Source Fool.com
